Description

Ecnoglutide (XW003) is a long-acting, cAMP-biased glucagon-like peptide 1 (GLP-1) receptor agonist. Ecnoglutide can be used for research of T2DM and obesity[1][2].–80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)–Metabolism-sugar/lipid metabolism–C194H304N48O61—-[1]Guo W, et al. Discovery of ecnoglutide – A novel, long-acting, cAMP-biased glucagon-like peptide-1 (GLP-1) analog. Mol Metab. 2023 Sep;75:101762.|[2]WHO Drug Information, Vol. 35, No. 4, 2021. Geneva: World Health Organization; 2022.–2459531-73-6–4284.76–98.61–[Ecnoglutide]–Metabolic Disease–H2O : 20 mg/mL (ultrasonic;adjust pH to 12 with 1M NaOH)|H2O : 25 mg/mL (ultrasonic)–GCGR—-GPCR/G Protein–Peptides